Indian stocks: Visit www.stage2stocks.com →

Arcturus Therapeutics Holdings Inc.

Stage 2 · Advancing · week 9

As of Oct 22, 2026, Arcturus Therapeutics Holdings is in Stage 2, the uptrend phase, now in week 9 (since Aug 26, 2026). It closed at $10.73, 36.6% below its 52-week high and above its 200-day average, which is rising.

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. More about the company

$10.73
-3.07% today
$305M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ARCT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S4 33w
S1 18w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 6w → S3 5w → S4 7w → S1 5w → S2 12w → S3 9w → S2 2w → S3 2w → S4 15w → S1 1w → S4 33w → S1 10w → S2 9w → S3 3w → S4 11w → S1 18w → S4 8w → S1 1w → S2 8w current
Total tracked: 164 weeks across 19 stage runs.

ARCT among Biotechnology366th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…366ARCTStage 2 · wk 922−19.3%
vs 52W High
-36.6%
$5.53 lo$16.93 hi
36.6% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
20.8%
200 DMA: $8.89 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.44x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-19.3%
3M
+94.0%
6M
+26.7%
YTD
+71.7%
1Y
-53.7%
Scan Membership
Breakout Watch
Latest: 2024-06-17
9 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 9 · Vol 0.44x
2026-10-21S2
Wk 8 · Vol 0.27x
2026-10-20S2
Wk 8 · Vol 0.81x
2026-10-19S2
Wk 8 · Vol 0.58x
2026-10-16S2
Wk 8 · Vol 0.77x
2026-10-15S2
Wk 8 · Vol 0.46x
2026-10-14S2
Wk 7 · Vol 0.55x
2026-10-13S2
Wk 7 · Vol 0.43x
2026-10-12S2
Wk 7 · Vol 0.39x
2026-10-09S2
Wk 7 · Vol 0.63x
2026-10-08S2
Wk 7 · Vol 0.64x
2026-10-07S2
Wk 6 · Vol 0.49x
Moving averages & range
50 DMA
$13.36
200 DMA
$8.89
52W High
$16.93
52W Low
$5.53
5D Low
$10.34
Resistance levels (recent highs)
20d High
$14.66
60d High
$16.93
120d High
$16.93
250d High
$16.93
Next resistance
+36.6%
to 20d High
ROE
-46.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.8

Arcturus Therapeutics Holdings: quick answers

What stage is Arcturus Therapeutics Holdings in?

As of Oct 22, 2026, Arcturus Therapeutics Holdings (ARCT) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 26, 2026 and is in week 9. What the four stages mean

Is Arcturus Therapeutics Holdings in an uptrend?

Yes. Arcturus Therapeutics Holdings is in a Stage 2 uptrend. It trades 20.8% above its 200-day average, which is rising.

How far is Arcturus Therapeutics Holdings from its 52-week high?

Arcturus Therapeutics Holdings closed at $10.73 on Oct 22, 2026, 36.6% below its 52-week high of $16.93. Its 52-week low is $5.53.

How has Arcturus Therapeutics Holdings performed over the past year?

As of Oct 22, 2026, Arcturus Therapeutics Holdings is down 53.7% over the past year and up 71.7% so far in 2026.

Which sector and industry is Arcturus Therapeutics Holdings in?

Arcturus Therapeutics Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.